# PRIMARY Ancillary Substudy

Study · id `cardio:ct-nct07103733` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07103733](<https://clinicaltrials.gov/study/NCT07103733>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07103733

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT07103733. Randomized; double masking; primary purpose basic science. Start 2023-10-16 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose basic science
- Phase: Not applicable
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT07103733, source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)
- Started: 2023-10-16 (actual) (ClinicalTrials.gov record NCT07103733, source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07103733, source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07103733, source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)
- Countries: United States; Germany; United Kingdom (ClinicalTrials.gov record NCT07103733, source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07103733-2026-09-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: PRIMARY Ancillary Substudy
- Condition: Mitral Valve Prolapse
- Condition: Left Ventricular Fibrosis
- Condition: Ventricular Arrhythmias
- Intervention (Procedure): Cardiac Magnetic Resonance Imaging
- Intervention (Device): ZioPatch Monitoring
- Intervention (Procedure): Myocardial Tissue Biopsy
- Lead sponsor: Annetine Gelijns
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral valve prolapse (`cardio:mitral-valve-prolapse`)
- Registry lists this organization as the lead sponsor: Annetine Gelijns (`cardio:org-annetine-gelijns`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 708640baef4100ffa419311a5bfc2595c5c4e050b442079e107b0bc0c452fff2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
